In patients included in the CATNON randomised phase III clinical trial, those harbouring tumours with non-R132H IDH1/2-mutations indeed had longer overall survival compared to patients harbouring IDH1R132H mutated tumours (Fig. 2c). Here, IDH1 is linked to neoplasm.